Other languages Immunocore Holdings plc

Equities

IMCR

US45258D1054

Real-time Estimate Cboe BZX Other stock markets 11:20:31 2024-06-10 am EDT			5-day change	1st Jan Change
40.49 ^USD	-2.86%		-4.89%	-40.50%

Jun. 01	Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	CI
Jun. 01	Transcript : Immunocore Holdings plc - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	Jun. 01
Immunocore Holdings plc Reports Updated Phase 1 Data of Brenetafusp (IMC-F106C), an ImmTAC Bispecific Targeting PRAME, in Immune Checkpoint Pre-treated Cutaneous Melanoma Patients at ASCO 2024	May. 31
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3	May. 29
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma	May. 29
Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director	May. 28
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	May. 08
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Immunocore Holdings Files Mixed-Securities Shelf Registration	Mar. 21
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises	Feb. 28
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial	Feb. 22
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Jan. 30
Immunocore Plans $300 Million Convertible Senior Notes Offering ; Shares Fall After-Hours	Jan. 29
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 29
Immunocore Holdings Insider Sold Shares Worth $305,781, According to a Recent SEC Filing	Jan. 05
Immunocore Plans to Boost Sales, Expand Access to Kimmtrak in 2024	Jan. 05
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline	Jan. 05
Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Immunocore's Q2 Net Loss Widens, Revenue Climbs	23-08-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immunocore Holdings plc

Equities

IMCR

US45258D1054

Other languages

Filters